# Novel Small Molecule Anti-Inflammatory Eye Drops for Ocular Graft Versus Host Disease

> **NIH NIH R44** · PULSAR LIFE SCIENCES, INC. · 2022 · $750,000

## Abstract

SUMMARY
Ocular graft versus host disease (OGVHD) is a severe ocular surface inflammatory disease (OSID), occurring
in patients undergoing allogenic hematopoietic stem cell transplantation (HSCT). OGVHD is characterized by
dry eye, meibomian gland dysfunction, conjunctival scarring, lid margin scarring, keratopathy, and corneal
ulceration, causing significant ocular morbidity and vision loss for affected patients. Presently, there are no
effective disease-modifying therapies for OGVHD. The purpose of this SBIR Phase II grant application is to
develop novel and effective therapies for the treatment of OGVHD and potentially other OSIDs. The current
proposal from Pulsar Life Sciences is focused on developing calcium/calmodulin-dependent protein kinase
kinase 2 (CaMKK2)-targeted therapies for ocular diseases. Our preliminary studies and the results from a Phase
1 STTR to Eyedesis Biosciences (parent company) demonstrate that murine OGVHD is associated with
conjunctival infiltration by T cells and MФ, two cell types in which CaMKK2 has been previously shown to be a
regulator of inflammatory cell function; topical application of the tool compound SMIC, STO-609, significantly
reduced murine OGVHD severity in vivo; and many compounds from a proprietary library of novel SMICs
invented by Eyedesis inhibited CaMKK2 activity in vitro. These findings support the hypothesis that novel
inhibitors of CaMKK2 can be developed to treat OGVHD. Eyedesis has successfully completed Phase 1 aims to
demonstrate that many novel SMICs were potent inhibitors of CaMKK2 in vitro, most novel SMICs were well
tolerated when applied topically to the eye, and two novel SMICs administered topically were efficacious in
treating murine OGVHD. In this follow-on Phase 2 SBIR application, Pulsar will complete lead optimization and
IND-enabling studies required for our filing of an IND application. Aim 1 will finalize lead optimization and select
the lead candidate, Aim 2 will perform the technical transfer to contract GMP drug manufacturer and contract
GMP drug formulation, establish CMC properties, and characterize formulation stability, and Aim 3 will perform
IND-enabling pharmacology and toxicology studies. The end deliverable will be to submit an IND application to
the FDA and perform the first-in-human clinical studies with this topical eyedrop for OGVHD.

## Key facts

- **NIH application ID:** 10334520
- **Project number:** 5R44EY029185-03
- **Recipient organization:** PULSAR LIFE SCIENCES, INC.
- **Principal Investigator:** Jindong Ding
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $750,000
- **Award type:** 5
- **Project period:** 2021-02-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10334520

## Citation

> US National Institutes of Health, RePORTER application 10334520, Novel Small Molecule Anti-Inflammatory Eye Drops for Ocular Graft Versus Host Disease (5R44EY029185-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10334520. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*